Artesunate + Amodiaquine tablets (50 +153)mg
Product information: Artesunate/amodiaquine tablet is a fixed-dose artemisinin-based combination therapy (ACT) indicated for the treatment of acute uncomplicated Plasmodium falciparum malaria.
It was launched in 2007 as an affordable treatment for malaria, devised by DNDi in partnership with Sanofi-Aventis.
The drug is patent free.
Early clinical trials showed that a once-a-day dosage was effective. It was subsequently clinically shown to be equally effective as artemether/lumefantrine (“Coartem”), although it is likely to be more effective in the field due to its simpler once-a-day dosage compared to artemether/lumefantrine twice-per-day dosage
Product Packaging – The dosages available for this product are:
Artesunate/Amodiaquine Tablets (50+153)mg
The Artesunate/Amodiaquine Tablets can be packaged(12+12)/box, 240box/box, or according to the customer’s specifications.